Navigation Links
Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Date:12/6/2011

s.

In the EU, Nplate is indicated for the treatment of splenectomized adult chronic ITP patients who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). Nplate may be considered as a second-line treatment for adult non-splenectomized ITP patients for whom surgery is contraindicated.

Nplate was named as a recipient of the U.S. Prix Galien 2009 "Best Biotechnology Product" award and also received the 2009 Scrip Awards for "Best New Drug." Nplate has also been honored with numerous awards throughout the EU, including a 2010 Prix Galien in France in the category of "Drugs for Rare Diseases," and the 2011 Prix Galien in Germany in the category of "Specialist Care." In September 2010, Nplate was awarded the 2010 International Prix Galien Award, an award granted every two years which recognizes the "best of the best" selected from previous national Prix Galien award recipients.

For more information about Nplate, please visit www.Nplate.com.

Important U.S. Nplate Safety Information

The risks associated with Nplate include progression of MDS to acute myelogenous leukemia (AML) in patients with MDS, thrombotic/thromboembolic complications, bone marrow reticulin formation and risk for bone marrow fibrosis, worsened thrombocytopenia after cessation of Nplate, and lack or loss of response to Nplate.  In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.

Important EU Nplate Safety Information

The most common side effects are headache, fatigue, arthralgia and myalgia.

The risks associated with Nplate include reoccurrence of thrombocytopenia, bleeding after cessation of treatment, increased bone marrow reticulin, thrombotic/thromboembolic complications, progression of existing MDS (in patients with MDS), loss of response to Nplate, and effects on red and white blood cells.

About Amgen
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
2. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
3. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
4. Amgen Announces 2011 Fourth Quarter Dividend
5. Amgen to Present at the UBS Global Life Sciences Conference
6. Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
7. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
8. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
9. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
10. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
11. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... As part of its philanthropic partnership ... Health Foundation funded a $3.25 million project to relocate ... the most up-to-date features and technology. , The new ... 45 staff members will begin moving from the current ... coming days. , The current pharmacy has been ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... , May 20, 2015 Research and Markets ... of the "Top Technologies in HW_Technical Insights" ... of this report evaluated technology trends in the Health ... that are likely to have an impact in the ... analysis of the top 10 health and wellness technologies ...
(Date:5/20/2015)... 20, 2015  Select Medical Corporation ("Select") (NYSE: ... Commission granted early termination of the waiting period ... 1976, as amended, applicable to the acquisition of ... joint venture that Select has created with Welsh, ... previously announced, MJ Acquisition Corporation has signed a ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... 12 Raptor Pharmaceuticals Corp.,(OTC Bulletin Board: RPTP), today ... clinical development subsidiary, will,present at the 2008 BIO International ... Diego Convention Center in San Diego, CA., Mr. ... 18, 2008 at 1:15p.m. (PT) in room 4 of ...
... MTA: CTIC) today announced that a single institutional investor,has ... Convertible,Senior Notes due 2011, with an initial conversion price ... 14.6 million shares of common stock,with an exercise price ... partial exercise of a previously granted,warrant right for the ...
... Organization Takes Prominent Position and ... WEST SENECA, N.Y., June 11 Palladian Muscular ... to,create a high-profile presence at a leading healthcare event ... Wednesday, June,18 to Friday, June 20, 2008., "We ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 3Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 4Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... of marine biologists has found that existing diversity in ... extreme temperature disturbances such as those predicted from ... on the species of algae living within corals may ... temperatures changes. The results will be published online in ...
... altitude medicine is a "natural research laboratory" for the ... can shed light on conditions and diseases that mimic ... top of mountains. Yves Allemann, MD, FESC, Swiss Cardiovascular ... Hospitalier Universitaire Vaudois, Lausanne, have assembled an international group ...
... Scientists at the University of Kentucky Markey Cancer Center ... enables tumor cells to spread to adjacent or distant parts ... opens the way to new lines of research aimed at ... by Peter Zhou, associate professor of molecular and cellular biochemistry ...
Cached Biology News:New study sheds light on corals' susceptibility to temperature change 2High-altitude research advances low-altitude medicine 2High-altitude research advances low-altitude medicine 3Key mechanism identified in metastatic breast cancer 2
... as an internal standard for the quantification ... spectrometry. 5-OxoETE is a polyunsaturated keto acid ... human neutrophils. It stimulates cytosolic calcium levels ... nM. 5-OxoETE selectively stimulates the migration and ...
... dsRNA Marker consists of ten double-stranded RNAs, ... 400, 500 and 1,000 base pairs. The ... for determinating sizes of double-stranded RNAs. A ... dsRNA Marker is adjusted to approximately 25 ...
... off-white solid. A nucleoside antibiotic that ... formation of N-glycosidic protein-carbohydrate linkages. Active ... bacteria, yeasts, fungi, and viruses. Inhibits ... on human T-lymphoblastoid cells. Also inhibits ...
... of enzymes involved in matrix degradation. Of ... ten exist in soluble form whereas MT-MMPs ... MT3-MMP also known as MMP14, MMP15, MMP16 ... them to the cell surface. They have ...
Biology Products: